nach oben

Current Cardiology Reports

Erschienen in:

01.04.2011

Stroke Prevention in Atrial Fibrillation: Atrial Appendage Closure

verfasst von: Cindy J. Fuller, Mark Reisman

Erschienen in: Current Cardiology Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The left atrial appendage (LAA) is the primary nonvalvular cause of cardioembolic stroke in patients with atrial fibrillation (AF). Warfarin and direct thrombin inhibitors such as dabigatran are presumed to prevent formation of LAA thrombus, and are first-line treatments to prevent ischemic stroke in AF. However, these medications carry many contraindications such as hemorrhage, and can interact with many drugs and supplements. Epicardial and endovascular techniques for occlusion of LAA are being explored, whether to mitigate the need for anticoagulation in patients at risk of bleeding or as a first-line therapy to reduce the risk of thromboembolic stroke. The purposes of this article are to 1) review the LAA structure and its potential contribution to ischemic stroke; 2) discuss the results of surgical and endovascular trials of LAA occlusion on risk of stroke and adverse events in AF patients; and 3) present early data on devices in development.

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983–8.PubMed

Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119–25.CrossRefPubMed

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449–57.

Benjamin EJ, Wolf PA, D’Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946–52.PubMed

Smith EE, Shobha N, Dai D et al. Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program. Circulation 2010; 122:1496–504.CrossRefPubMed

Petrea RE, Beiser AS, Seshadri S et al. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke 2009; 40:1032–7.CrossRefPubMed

Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48:854–906.CrossRefPubMed

Holbrook AM, Pereira JA, Labiris R et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095–106.CrossRefPubMed

Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–51.CrossRefPubMed

10.

Thambidorai SK, Murray RD, Parakh K et al. Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol 2005; 96:935–41.CrossRefPubMed

11.

Healey JS, Crystal E, Lamy A et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150:288–93.CrossRefPubMed

12.

Bayard YL, Omran H, Neuzil P et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 2010; 6:220–6.CrossRefPubMed

13.

Ernst G, Stollberger C, Abzieher F et al. Morphology of the left atrial appendage. Anat Rec 1995; 242:553–61.CrossRefPubMed

14.

Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999; 82:547–54.PubMed

15.

Veinot JP, Harrity PJ, Gentile F et al. Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination. Circulation 1997; 96:3112–5.PubMed

16.

• Su P, McCarthy KP, Ho SY. Occluding the left atrial appendage: anatomical considerations. Heart 2008; 94:1166–70. The authors conclude that the design of occlusion devices needs to take the anatomy of the LAA and surrounding structures of the left atrium into consideration to reduce the risk of peri- and postprocedural adverse events. CrossRefPubMed

17.

Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23:961–9.CrossRefPubMed

18.

Handke M, Harloff A, Hetzel A et al. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation—a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr 2005; 18:1366–72.CrossRefPubMed

19.

Beinart R, Heist EK, Newell JB et al. Left Atrial Appendage Dimensions Predict the Risk of Stroke/TIA in Patients With Atrial Fibrillation. J Cardiovasc Electrophysiol 2010, in press.

20.

Hart RG, Pearce LA, Albers GW et al. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69:546–54.CrossRef

21.

Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864–70.CrossRefPubMed

22.

Puwanant S, Varr BC, Shrestha K et al. Role of the CHADS₂ score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009; 54:2032–9.CrossRefPubMed

23.

Tang RB, Liu XH, Kalifa J et al. Body mass index and risk of left atrial thrombus in patients with atrial fibrillation. Am J Cardiol 2009; 104:1699–703.CrossRefPubMed

24.

• Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263–72. The authors introduce the expanded CHADS ₂ -VASc score to assess risk of stroke in patients with AF in this article, which adds sex, diagnosis of vascular disease, and age between 65 and 74 years as risk factors to the CHADS ₂ score. CrossRefPubMed

25.

Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731–8.CrossRefPubMed

26.

Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369–429.PubMed

27.

Uemura T, Kaikita K, Yamabe H et al. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. Thromb Res 2009; 124:28–32.CrossRefPubMed

28.

Duygu H, Barisik V, Kurt H et al. Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation. Europace 2008; 10:210–214.CrossRefPubMed

29.

Alberti S, Angeloni G, Tamburrelli C et al. Platelet-leukocyte mixed conjugates in patients with atrial fibrillation. Platelets 2009; 20:235–41.CrossRefPubMed

30.

Schneider B, Stollberger C, Sievers HH. Surgical closure of the left atrial appendage—a beneficial procedure? Cardiology 2005; 104:127–32.CrossRefPubMed

31.

Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interact Cardiovasc Thorac Surg 2010; 10:306–11.CrossRefPubMed

32.

Kanderian AS, Gillinov AM, Pettersson GB et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008; 52:924–9.CrossRefPubMed

33.

Salzberg SP, Plass A, Emmert MY et al. Left atrial appendage clip occlusion: early clinical results. J Thorac Cardiovasc Surg 2010; 139:1269–74.CrossRefPubMed

34.

Bruce CJ, Stanton CM, Asirvatham SJ et al. Percutaneous epicardial left atrial appendage closure: intermediate-term results. J Cardiovasc Electrophysiol 2010, in press.

35.

McCarthy PM, Lee R, Foley JL et al. Occlusion of canine atrial appendage using an expandable silicone band. J Thorac Cardiovasc Surg 2010; 140:885–9.CrossRefPubMed

36.

Singh SM, Dukkipati SR, d’Avila A et al. Percutaneous left atrial appendage closure with an epicardial suture ligation approach: a prospective randomized pre-clinical feasibility study. Heart Rhythm 2010; 7:370–6.CrossRefPubMed

37.

Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005; 46:9–14.CrossRefPubMed

38.

•• Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374:534–42. This article discusses the PROTECT AF trial, which showed that endovascular LAA occlusion was not inferior to warfarin in prevention of stroke in AF patients. CrossRefPubMed

39.

Sievert H, Lesh MD, Trepels T et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002; 105:1887–9.CrossRefPubMed

40.

Block PC, Burstein S, Casale PN et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv 2009; 2:594–600.CrossRefPubMed

41.

Park JW, Leithauser B, Gerk U et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes. J Invasive Cardiol 2009; 21:446–50.PubMed

42.

Sick PB, Schuler G, Hauptmann KE et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007; 49:1490–5.CrossRefPubMed

43.

Schwartz RS, Holmes DR, Van Tassel RA et al. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. J Am Coll Cardiol Intv 2010; 3:870–7.

44.

Hankey GJ. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? Curr Opin Neurol 2010; 23:65–72.CrossRefPubMed

45.

Meier B, Palacios I, Windecker S et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003; 60:417–22.CrossRefPubMed

46.

Rodes-Cabau J, Champagne J, Bernier M. Transcatheter closure of the left atrial appendage: initial experience with the Amplatzer cardiac plug device. Catheter Cardiovasc Interv 2010; 76:186–92.CrossRefPubMed

Titel: Stroke Prevention in Atrial Fibrillation: Atrial Appendage Closure
verfasst von: Cindy J. Fuller
Mark Reisman
Publikationsdatum: 01.04.2011
Verlag: Current Science Inc.
Erschienen in: Current Cardiology Reports / Ausgabe 2/2011
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-010-0162-1

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Variation of Heart-to-Mediastinal Ratio in 123I-mIBG Cardiac Sympathetic Imaging: Its Affecting Factors and Potential Corrections

Imaging of Coronary Inflammation with FDG-PET: Feasibility and Clinical Hurdles

Microvascular Angina: Assessment of Coronary Blood Flow, Flow Reserve, and Metabolism

Metabolic Imaging for Identifying Antecedent Myocardial Ischemia and Acute Coronary Syndrome in the Emergency Department